Payment overview · 2025
General Payments
$875.39
32 reported records · 19 companies
Healthcare provider profile · identity verified
Gregory G. Schnier, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · BURLINGTON, NC · NPI 1740245943
Verified facts
What the public records show
CMS Open Payments records show Gregory G. Schnier, MD received $875.39 in general payments during 2025 across 32 reported records.
Abbott Laboratories accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $215.43 | 24.6% | 5 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $80.65 | 9.2% | 4 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $63.11 | 7.2% | 2 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $53.37 | 6.1% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $42.92 | 4.9% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $40.03 | 4.6% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $39.55 | 4.5% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $37.92 | 4.3% | 2 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $36.00 | 4.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$33.80 | 3.9% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $33.66 | 3.9% | 1 | 2025 |
| Flowphysix Inc | Unresolved — no canonical attribution shown | $30.74 | 3.5% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $30.37 | 3.5% | 2 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $29.80 | 3.4% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $28.16 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.01 | 2.6% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $20.75 | 2.4% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $19.31 | 2.2% | 1 | 2025 |
| Acist Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.81 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $875.39 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $167.17 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $63.11 | 2 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $60.04 | 3 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $53.37 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $53.37 | 1 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $53.37 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $53.37 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $42.92 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $42.92 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $42.92 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $40.03 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $39.55 | 2 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $33.80 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $33.66 | 1 | 2025 |
Source payment records
|
|||||
| FLOWRUNNER Normalized: flowrunner |
Device | Flowphysix Inc | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $30.37 | 2 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $29.80 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $24.49 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Becton, Dickinson and Company | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH ALPHA Normalized: zenith alpha |
Device | Cook Medical LLC | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Crosser IQ Normalized: crosser iq |
Device | Bard Peripheral Vascular, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| CVI Systems Normalized: cvi systems |
Device | Acist Medical Systems, Inc. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| HI-TORQUE COMMAND Normalized: hi torque command |
Device | Abbott Laboratories | $5.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 220 | 56 |
| Eliquis | Apixaban | 82 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 13 |
| Brilinta | Ticagrelor | 14 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $875.39 · 32 records | Abbott Laboratories | ANGIO-SEAL, APLIGRAF, ARTEGRAFT VASCULAR GRAFT, AURYON LASER SYSTEM 100-120 VAC, COLLAGENASE SANTYL, CVI Systems, Crosser IQ, ELIQUIS, ENDURANT IIS, ESPRIT, ETHICON, FLOWRUNNER, Flexitouch Plus, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, HI-TORQUE COMMAND, Integra, Integra Dermal Regeneration Template, LUTONIX Drug Coated Balloon, Nimbl, OPTIS, PAXLOVID, PERCLOSE PROGLIDE, PRIMATRIX, QUTENZA, SURGICEL NU-KNIT, SURGIFLO Hemostatic Matrix, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VISTASEAL, ZENITH ALPHA, ZENITH SPIRAL-Z | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error